Search
AIM ImmunoTech Inc
AIMAdd to Watchlist
0.279USD
-0.017-5.84%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
2.29MMarket Cap
LossP/E TTM
More Details of AIM ImmunoTech Inc Company
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
AIM ImmunoTech Inc Info
Ticker SymbolAIM
Company nameAIM ImmunoTech Inc
IPO dateJul 12, 1996
CEOEquels (Thomas K)
Number of employees21
Security typeOrdinary Share
Fiscal year-endJul 12
Address2117 Sw Highway 484
CityOCALA
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code32801
Phone13524487797
Websitehttps://aimimmuno.com/
Ticker SymbolAIM
IPO dateJul 12, 1996
CEOEquels (Thomas K)
Company Executives of AIM ImmunoTech Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
+39.13%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
+97.74%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+0.04%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
+39.13%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
+97.74%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+0.04%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
FAQs
Who are the top five shareholders of AIM ImmunoTech Inc?
The top five shareholders of AIM ImmunoTech Inc are: Mr. Thomas K. Equels, Esq., J.D.
How many institutions hold shares of AIM ImmunoTech Inc (AIM)?
As of 2026Q1, 57 institutions hold shares of AIM ImmunoTech Inc, with a combined market value of approximately 105.74K, accounting for 1.30% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -74291.00.
